Aligos Therapeutics, Inc. (ALGS) Institutional Ownership

Ownership Summary

Aligos Therapeutics, Inc. (NASDAQ:ALGS) is held by 40 institutional investors per 13F filings through December 2025.

• Their combined ownership stood at 27.1% of outstanding shares in December 2025, up from 25.6% in September 2025.
• They increased total shares held in Aligos Therapeutics by 23.81% from the prior quarter, while the number of investors in ALGS increased 14.29% year over year.
• Activity in ALGS broke down as 21 buyers, 8 sellers, and 11 unchanged among 40 total holders.
• In total, institutional investors held 2.81Mn shares in Aligos Therapeutics as of December 2025, up by 540.55K shares quarter on quarter, and up 1.19Mn shares year over year.
• Deep Track Capital, LP holds the largest position in ALGS at 444.11K shares as of December 31, 2025, or 4.28% of shares outstanding.
• The largest buyers of Aligos Therapeutics for the quarter ending December 2025 were MARSHALL WACE, LLP (268.66K), SummitTX Capital, L.P. (139.42K), Verition Fund Management LLC (71.25K), TWO SIGMA INVESTMENTS, LP (41.65K), CITADEL ADVISORS LLC (41.52K).
• The biggest sellers of Aligos Therapeutics for the quarter ending December 2025 included Woodline Partners LP (179.03K), UBS Group AG (15.82K), Morgan Stanley (8.76K), Wells Fargo & Company/Mn (1.67K), Jpmorgan Chase & Co (1.11K).
• According to Business Quant data, leading holders of ALGS for December 2025 are Deep Track Capital, LP (444.11K), Alyeska Investment Group, L.P. (412.0K), Sio Capital Management, LLC (335.94K), Woodline Partners LP (289.17K), MARSHALL WACE, LLP (268.66K), VANGUARD GROUP INC (200.4K), SummitTX Capital, L.P. (139.42K), RENAISSANCE TECHNOLOGIES LLC (85.44K), BAKER BROS. ADVISORS LP (83.06K), TWO SIGMA INVESTMENTS, LP (80.65K).